Evidence map›Paper›PMID 34603477›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2021

Microencapsulated Recombinant Human Epidermal Growth Factor Ameliorates Osteoarthritis in a Murine Model.

Shih-Chao Lin, Xiang Zhang, Shiow-Yi Chen, Chi-Chien Lin, Yen-Shuo Chiu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Shih-Chao LinBachelor Degree Program in Marine Biotechnology, College of Life Sciences, National Taiwan Ocean University, Keelung 20224, Taiwan.ORCID https://orcid.org/0000-0003-2942-5937
Xiang ZhangDepartment of Physiology and Pharmacology, Karolinska Institute, Stockholm SE-171 77, Sweden.
Shiow-Yi ChenDepartment of Bioscience and Biotechnology, National Taiwan Ocean University, Keelung City 20224, Taiwan.ORCID https://orcid.org/0000-0001-5734-4697
Chi-Chien LinInstitute of Biomedical Sciences, National Chung Hsing University, Taichung 402, Taiwan.ORCID https://orcid.org/0000-0002-1464-0231
Yen-Shuo ChiuDepartment of Orthopedics, Shuang Ho Hospital, New Taipei 235, Taiwan.ORCID https://orcid.org/0000-0001-8803-2362
National Taiwan Ocean University · TWKarolinska Institutet · SENational Chung Hsing University · TWTaipei Medical University-Shuang Ho Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis, a highly age-related and chronic inflammatory disorder with cartilage loss, causes patients difficultly in movement; there is no efficient and sustainable remedy for osteoarthritis currently. Although hyaluronic acid (HA) and platelet-rich plasma (PRP) have been used to alleviate osteoarthritis, the effects could be short and multiple injections might be required. To address this issue, we exploited the property of chitosan to encapsulate recombinant human epidermal growth factor and obtained microencapsulated rhEGF (Me-rhEGF). In the current study, we induced the osteoarthritis-like symptoms with monosodium iodoacetate (MIA) in rats and investigated the therapeutic effects of Me-rhEGF. Following administration of HA/Me-rhEGF

Identifiers

PMID34603477
PMCPMC8483914
OpenAlexW3199944584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.